Overview

A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the safety and pharmacokinetics of L-ofloxacin (RWJ 25213) in patients with HIV infection.
Phase:
Phase 1
Details
Lead Sponsor:
R W Johnson Pharmaceutical Research Institute
Treatments:
Levofloxacin
Ofloxacin